JP2020522543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522543A5 JP2020522543A5 JP2019567598A JP2019567598A JP2020522543A5 JP 2020522543 A5 JP2020522543 A5 JP 2020522543A5 JP 2019567598 A JP2019567598 A JP 2019567598A JP 2019567598 A JP2019567598 A JP 2019567598A JP 2020522543 A5 JP2020522543 A5 JP 2020522543A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- motomeko
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127275A JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516489P | 2017-06-07 | 2017-06-07 | |
| US62/516,489 | 2017-06-07 | ||
| US201862614801P | 2018-01-08 | 2018-01-08 | |
| US62/614,801 | 2018-01-08 | ||
| PCT/EP2018/065071 WO2018224609A1 (en) | 2017-06-07 | 2018-06-07 | Therapeutic antibodies based on mutated igg hexamers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127275A Division JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522543A JP2020522543A (ja) | 2020-07-30 |
| JP2020522543A5 true JP2020522543A5 (https=) | 2021-07-26 |
Family
ID=62636167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567598A Pending JP2020522543A (ja) | 2017-06-07 | 2018-06-07 | 変異ＩｇＧ六量体に基づく治療用抗体 |
| JP2023127275A Withdrawn JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127275A Withdrawn JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200247897A1 (https=) |
| EP (1) | EP3635005A1 (https=) |
| JP (2) | JP2020522543A (https=) |
| KR (1) | KR20200027944A (https=) |
| CN (1) | CN111328335A (https=) |
| BR (1) | BR112019025328A2 (https=) |
| MA (1) | MA49259A (https=) |
| MX (1) | MX2019014407A (https=) |
| TW (1) | TW201919692A (https=) |
| WO (1) | WO2018224609A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250140128A (ko) | 2017-02-10 | 2025-09-24 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
| BR112020022179A2 (pt) | 2018-05-03 | 2021-02-02 | Genmab B.V. | primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit. |
| EP3966241A1 (en) * | 2019-05-09 | 2022-03-16 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| KR20220130724A (ko) * | 2020-01-16 | 2022-09-27 | 젠맵 에이/에스 | Cd38 항체의 제제 및 그의 용도 |
| US20230293680A1 (en) * | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| CN100506277C (zh) | 2001-11-01 | 2009-07-01 | Uab研究基金会 | 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP3424951A1 (en) | 2007-06-21 | 2019-01-09 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| WO2010138725A1 (en) | 2009-05-28 | 2010-12-02 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN102654260B (zh) | 2011-09-29 | 2014-09-03 | 北京京东方光电科技有限公司 | 一种背光源和液晶显示器 |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| BR112015000167B1 (pt) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| MA43365A (fr) * | 2015-12-01 | 2018-10-10 | Genmab Bv | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci |
-
2018
- 2018-06-07 CN CN201880050867.4A patent/CN111328335A/zh active Pending
- 2018-06-07 JP JP2019567598A patent/JP2020522543A/ja active Pending
- 2018-06-07 EP EP18731987.6A patent/EP3635005A1/en active Pending
- 2018-06-07 US US16/618,722 patent/US20200247897A1/en not_active Abandoned
- 2018-06-07 MA MA049259A patent/MA49259A/fr unknown
- 2018-06-07 WO PCT/EP2018/065071 patent/WO2018224609A1/en not_active Ceased
- 2018-06-07 TW TW107119651A patent/TW201919692A/zh unknown
- 2018-06-07 KR KR1020207000017A patent/KR20200027944A/ko not_active Ceased
- 2018-06-07 MX MX2019014407A patent/MX2019014407A/es unknown
- 2018-06-07 BR BR112019025328-9A patent/BR112019025328A2/pt not_active Application Discontinuation
-
2023
- 2023-08-03 JP JP2023127275A patent/JP2023145720A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522543A5 (https=) | ||
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| JP2019500869A5 (https=) | ||
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| JP2019501151A5 (https=) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2021515566A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| CN113825527A (zh) | 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合 | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| ES2951864T3 (es) | Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama | |
| JPWO2020232019A5 (https=) | ||
| RU2836467C2 (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| KR102956075B1 (ko) | 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합 | |
| CN121175334A (zh) | 在治疗癌症中的使用pd-l1抑制剂的新辅助免疫疗法 | |
| CA3009161C (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
| CN116615238A (zh) | 用于治疗癌症和减轻细胞因子释放综合征的抗体组合 | |
| CN120152716A (zh) | 包括抗cd19抗体和ezh2调节剂的治疗 | |
| RU2023110743A (ru) | Биспецифические антитела к pd-1/cd40 и их применение | |
| NZ743316A (en) | Anti-dr5 antibodies and methods of use thereof | |
| RU2019128199A (ru) | 1-(4-амино-5-бром-6-(1h-пиразол-1-ил)пиримидин-2-ил)-1h-пиразол-4-ол и его применение в лечении рака | |
| NZ743316B2 (en) | Anti-dr5 antibodies and methods of use thereof | |
| EA042623B1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли |